343 related articles for article (PubMed ID: 29404583)
21. Serum neurofilament light chain and glial fibrillary acidic protein for predicting response to apheresis in steroid-refractory multiple sclerosis relapses.
Vardakas I; Dorst J; Huss A; Mayer B; Fangerau T; Taranu D; Tumani H; Senel M
Eur J Neurol; 2024 May; ():e16323. PubMed ID: 38700322
[TBL] [Abstract][Full Text] [Related]
22. Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease).
Weinstock-Guttman B; Ramanathan M; Lincoff N; Napoli SQ; Sharma J; Feichter J; Bakshi R
Arch Neurol; 2006 Jul; 63(7):957-63. PubMed ID: 16831964
[TBL] [Abstract][Full Text] [Related]
23. Response to Therapeutic Plasma Exchange as a Rescue Treatment in Clinically Isolated Syndromes and Acute Worsening of Multiple Sclerosis: A Retrospective Analysis of 90 Patients.
Ehler J; Koball S; Sauer M; Mitzner S; Hickstein H; Benecke R; Zettl UK
PLoS One; 2015; 10(8):e0134583. PubMed ID: 26244762
[TBL] [Abstract][Full Text] [Related]
24. Natalizumab therapy for highly active pediatric multiple sclerosis.
Kornek B; Aboul-Enein F; Rostasy K; Milos RI; Steiner I; Penzien J; Hellwig K; Pitarokoili K; Storm van's Gravesande K; Karenfort M; Blaschek A; Meyer A; Seidl R; Debelic D; Vass K; Prayer D; Kristoferitsch W; Bayas A
JAMA Neurol; 2013 Apr; 70(4):469-75. PubMed ID: 23420110
[TBL] [Abstract][Full Text] [Related]
25. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: Brainstem involvement - frequency, presentation and outcome.
Jarius S; Kleiter I; Ruprecht K; Asgari N; Pitarokoili K; Borisow N; Hümmert MW; Trebst C; Pache F; Winkelmann A; Beume LA; Ringelstein M; Stich O; Aktas O; Korporal-Kuhnke M; Schwarz A; Lukas C; Haas J; Fechner K; Buttmann M; Bellmann-Strobl J; Zimmermann H; Brandt AU; Franciotta D; Schanda K; Paul F; Reindl M; Wildemann B;
J Neuroinflammation; 2016 Nov; 13(1):281. PubMed ID: 27802825
[TBL] [Abstract][Full Text] [Related]
26. Immunologic Effects of Metformin and Pioglitazone Treatment on Metabolic Syndrome and Multiple Sclerosis.
Negrotto L; Farez MF; Correale J
JAMA Neurol; 2016 May; 73(5):520-8. PubMed ID: 26953870
[TBL] [Abstract][Full Text] [Related]
27. Short-term effect of additional apheresis on visual acuity changes in patients with steroid-resistant optic neuritis in neuromyelitis optica spectrum disorders.
Mori S; Kurimoto T; Ueda K; Nakamura M
Jpn J Ophthalmol; 2018 Jul; 62(4):525-530. PubMed ID: 29802557
[TBL] [Abstract][Full Text] [Related]
28. A case report of double filtration plasmapheresis in an acute episode of multiple sclerosis.
Ramunni A; De Robertis F; Brescia P; Saliani MT; Amoruso M; Prontera M; Dimonte E; Trojano M; Coratelli P
Ther Apher Dial; 2008 Jun; 12(3):250-4. PubMed ID: 18503704
[TBL] [Abstract][Full Text] [Related]
29. [Tryptophan immunoadsorption for multiple sclerosis and neuromyelitis optica: therapy option for acute relapses during pregnancy and breastfeeding].
Hoffmann F; Kraft A; Heigl F; Mauch E; Koehler J; Harms L; Kümpfel T; Köhler W; Klingel R; Fassbender C; Schimrigk S
Nervenarzt; 2015 Feb; 86(2):179-86. PubMed ID: 25604838
[TBL] [Abstract][Full Text] [Related]
30. Acute disseminated encephalomyelitis, multiphasic disseminated encephalomyelitis and multiple sclerosis in children.
Dale RC; de Sousa C; Chong WK; Cox TC; Harding B; Neville BG
Brain; 2000 Dec; 123 Pt 12():2407-22. PubMed ID: 11099444
[TBL] [Abstract][Full Text] [Related]
31. [Plasma exchange therapy for steroid-unresponsive multiple sclerosis relapses: clinical experience with 16 patients].
Schilling S; Linker RA; König FB; Koziolek M; Bähr M; Müller GA; Paulus W; Gärtner J; Brück W; Chan A; Gold R
Nervenarzt; 2006 Apr; 77(4):430-8. PubMed ID: 16341736
[TBL] [Abstract][Full Text] [Related]
32. Brain abnormalities in neuromyelitis optica.
Pittock SJ; Lennon VA; Krecke K; Wingerchuk DM; Lucchinetti CF; Weinshenker BG
Arch Neurol; 2006 Mar; 63(3):390-6. PubMed ID: 16533966
[TBL] [Abstract][Full Text] [Related]
33. Characterization of tissue damage in multiple sclerosis by nuclear magnetic resonance.
Barkhof F; van Walderveen M
Philos Trans R Soc Lond B Biol Sci; 1999 Oct; 354(1390):1675-86. PubMed ID: 10603619
[TBL] [Abstract][Full Text] [Related]
34. Neurologic diseases of the central nervous system with pathophysiologically relevant autoantibodies--perspectives for immunoadsorption.
Klingel R; Heibges A; Fassbender C
Atheroscler Suppl; 2013 Jan; 14(1):161-5. PubMed ID: 23357159
[TBL] [Abstract][Full Text] [Related]
35. Disease Course and Treatment Responses in Children With Relapsing Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.
Hacohen Y; Wong YY; Lechner C; Jurynczyk M; Wright S; Konuskan B; Kalser J; Poulat AL; Maurey H; Ganelin-Cohen E; Wassmer E; Hemingway C; Forsyth R; Hennes EM; Leite MI; Ciccarelli O; Anlar B; Hintzen R; Marignier R; Palace J; Baumann M; Rostásy K; Neuteboom R; Deiva K; Lim M
JAMA Neurol; 2018 Apr; 75(4):478-487. PubMed ID: 29305608
[TBL] [Abstract][Full Text] [Related]
36. Transdermal application of myelin peptides in multiple sclerosis treatment.
Walczak A; Siger M; Ciach A; Szczepanik M; Selmaj K
JAMA Neurol; 2013 Sep; 70(9):1105-9. PubMed ID: 23817921
[TBL] [Abstract][Full Text] [Related]
37. Association between immediate initiation of intramuscular interferon beta-1a at the time of a clinically isolated syndrome and long-term outcomes: a 10-year follow-up of the Controlled High-Risk Avonex Multiple Sclerosis Prevention Study in Ongoing Neurological Surveillance.
Kinkel RP; Dontchev M; Kollman C; Skaramagas TT; O'Connor PW; Simon JH;
Arch Neurol; 2012 Feb; 69(2):183-90. PubMed ID: 21987393
[TBL] [Abstract][Full Text] [Related]
38. Apheresis treatment in autoimmune neurological diseases: Predictors of good clinical outcome and success of follow-up therapy with B-cell depletion.
Fousse M; Fassbender K; Schunk SJ; Schmidt T; Stögbauer J
J Neurol Sci; 2024 Jun; 461():123050. PubMed ID: 38768532
[TBL] [Abstract][Full Text] [Related]
39. Clinical course, pathological correlations, and outcome of biopsy proved inflammatory demyelinating disease.
Pittock SJ; McClelland RL; Achenbach SJ; Konig F; Bitsch A; Brück W; Lassmann H; Parisi JE; Scheithauer BW; Rodriguez M; Weinshenker BG; Lucchinetti CF
J Neurol Neurosurg Psychiatry; 2005 Dec; 76(12):1693-7. PubMed ID: 16291895
[TBL] [Abstract][Full Text] [Related]
40. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
